Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment

被引:35
作者
Fellgiebel, A
Siessmeier, T
Scheurich, A
Winterer, G
Bartenstein, P
Schmidt, LG
Müller, MJ
机构
[1] Johannes Gutenberg Univ Mainz, Dept Psychiat, D-55131 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany
关键词
Alzheimer disease; biomarker; mild cognitive impairment; MCI; phospho-tau; FDG-PET; early diagnosis;
D O I
10.1016/j.biopsych.2004.05.014
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Mild cognitive impairment is considered to be a transitional stage between normal aging and dementia. Phosphorylated tau protein in cerebrospinal fluid and even more decrements of cerebral glucose metabolism in parietal, temporal, or cingulate regions have shown favorable specificity for the diagnosis of Alzheimer dementia and could be useful supplementary tools to determine Alzheimer pathology in early stages. Methods. We measured cerebrospinal fluid tau phosphorylated at threonine 181 protein, cerebrospinal,fluid total tau, and cerebral glucose metabolism using 18F-fluoro-2-deoxy-D-glucose positron emission tomography in 16patients with mild cognitive impairment and age-matcbed control subjects. Results. Alzheimer-typical patterns of cerebral glucose metabolism were significantly related to elevated phosphorylated tau levels (p =.009) but not to elevated total tau levels. In six of seven mild cognitive impairment patients with increased phosphorylated tau concentrations, Alzheimer disease-typical positron emission tomography patterns were found. Phosphorylated tau measurement separated patients with and without Alzheimer disease-typical positron emission tomography findings with a sensitivity of 85.7% and a specificity of 88.9%. Conclusions. Unlike total tau levels, elevated phosphorylated tau levels were strictly related to Alzheimer-typical-pattems of cerebral glucose metabolism in mild cognitive impairment patients. The results can be interpreted as validation of phosphorylated tau measurements for detecting Alzheimer disease in mild cognitive impairment patients.
引用
收藏
页码:279 / 283
页数:5
相关论文
共 33 条
[1]   Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Blennow, K .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 :47-51
[2]   Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease [J].
Augustinack, JC ;
Schneider, A ;
Mandelkow, EM ;
Hyman, BT .
ACTA NEUROPATHOLOGICA, 2002, 103 (01) :26-35
[3]  
Bartenstein P, 1997, J NUCL MED, V38, P1095
[4]  
Berent S, 1999, J PSYCHIAT RES, V33, P7
[5]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[6]   Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J].
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Tapiola, T ;
Arai, H ;
Blennow, K ;
Andreasen, N ;
Hofmann-Kiefer, K ;
DeBernardis, J ;
Kerkman, D ;
McCulloch, C ;
Kohnken, R ;
Padberg, F ;
Pirttilä, T ;
Schapiro, MB ;
Rapoport, SI ;
Möller, HJ ;
Davies, P ;
Hampel, H .
ARCHIVES OF NEUROLOGY, 2002, 59 (08) :1267-1272
[7]   CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects [J].
Buerger, K ;
Teipel, SJ ;
Zinkowski, R ;
Blennow, K ;
Arai, H ;
Engel, R ;
Hofmann-Kiefer, K ;
McCulloch, C ;
Ptok, U ;
Heun, R ;
Andreasen, N ;
DeBernardis, J ;
Kerkman, D ;
Moeller, HJ ;
Davies, P ;
Hampel, H .
NEUROLOGY, 2002, 59 (04) :627-629
[8]   Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment [J].
Chételat, G ;
Desgranges, B ;
de la Sayette, V ;
Viader, F ;
Berkouk, K ;
Landeau, B ;
Lalevée, C ;
Le Doze, F ;
Dupuy, B ;
Hannequin, D ;
Baron, JC ;
Eustache, F .
BRAIN, 2003, 126 :1955-1967
[9]   Mild cognitive impairment -: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? [J].
Chételat, G ;
Desgranges, B ;
de la Sayette, V ;
Viader, F ;
Eustache, F ;
Baron, JC .
NEUROLOGY, 2003, 60 (08) :1374-1377
[10]   The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET:: relationship to degree of deterioration [J].
Desgranges, B ;
Baron, JC ;
Lalevée, C ;
Giffard, B ;
Viader, F ;
de la Sayette, V ;
Eustache, F .
BRAIN, 2002, 125 :1116-1124